192 related articles for article (PubMed ID: 24162827)
1. PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression.
Muh CR; Joshi S; Singh AR; Kesari S; Durden DL; Makale MT
J Neurooncol; 2014 Jan; 116(1):89-97. PubMed ID: 24162827
[TBL] [Abstract][Full Text] [Related]
2. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
[TBL] [Abstract][Full Text] [Related]
3. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
Fang J; Ding M; Yang L; Liu LZ; Jiang BH
Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033
[TBL] [Abstract][Full Text] [Related]
4. MDM2 regulates hypoxic hypoxia-inducible factor 1α stability in an E3 ligase, proteasome, and PTEN-phosphatidylinositol 3-kinase-AKT-dependent manner.
Joshi S; Singh AR; Durden DL
J Biol Chem; 2014 Aug; 289(33):22785-22797. PubMed ID: 24982421
[TBL] [Abstract][Full Text] [Related]
5. Anti-Tumor Effects of Sodium Meta-Arsenite in Glioblastoma Cells with Higher Akt Activities.
Lee EJ; Sung JY; Koo KH; Park JB; Kim DH; Shim J; Lee CH; Park J; Kim YN
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33256086
[TBL] [Abstract][Full Text] [Related]
6. A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1α and HIF2α stability and tumor growth, angiogenesis, and metastasis.
Joshi S; Singh AR; Zulcic M; Durden DL
Mol Cancer Res; 2014 Oct; 12(10):1520-31. PubMed ID: 25103499
[TBL] [Abstract][Full Text] [Related]
7. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial therapy with adenoviral-mediated PTEN and a PI3K inhibitor suppresses malignant glioma cell growth in vitro and in vivo by regulating the PI3K/AKT signaling pathway.
Nan Y; Guo L; Song Y; Wang L; Yu K; Huang Q; Zhong Y
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1477-1487. PubMed ID: 28401302
[TBL] [Abstract][Full Text] [Related]
9. 2ME2 inhibits the activated hypoxia-inducible pathways by cabozantinib and enhances its efficacy against medullary thyroid carcinoma.
Lin H; Jiang X; Zhu H; Jiang W; Dong X; Qiao H; Sun X; Jiang H
Tumour Biol; 2016 Jan; 37(1):381-91. PubMed ID: 26219898
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of action of 2-methoxyestradiol: new developments.
Mooberry SL
Drug Resist Updat; 2003 Dec; 6(6):355-61. PubMed ID: 14744499
[TBL] [Abstract][Full Text] [Related]
11. PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
Goodwin CR; Lal B; Ho S; Woodard CL; Zhou X; Taeger A; Xia S; Laterra J
Anticancer Drugs; 2011 Oct; 22(9):905-12. PubMed ID: 21654317
[TBL] [Abstract][Full Text] [Related]
12. The HIF1α-PDGFD-PDGFRα axis controls glioblastoma growth at normoxia/mild-hypoxia and confers sensitivity to targeted therapy by echinomycin.
Peng G; Wang Y; Ge P; Bailey C; Zhang P; Zhang D; Meng Z; Qi C; Chen Q; Chen J; Niu J; Zheng P; Liu Y; Liu Y
J Exp Clin Cancer Res; 2021 Sep; 40(1):278. PubMed ID: 34470658
[TBL] [Abstract][Full Text] [Related]
13. PTEN activation sensitizes breast cancer to PI3-kinase inhibitor through the β-catenin signaling pathway.
Ren Y; Zhou X; Qi Y; Li G; Mei M; Yao Z
Oncol Rep; 2012 Sep; 28(3):943-8. PubMed ID: 22710837
[TBL] [Abstract][Full Text] [Related]
14. Isolinderalactone suppresses human glioblastoma growth and angiogenic activity in 3D microfluidic chip and in vivo mouse models.
Park JH; Kim MJ; Kim WJ; Kwon KD; Ha KT; Choi BT; Lee SY; Shin HK
Cancer Lett; 2020 May; 478():71-81. PubMed ID: 32173479
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Synthetic Vulnerability of
Chen C; Zhu S; Zhang X; Zhou T; Gu J; Xu Y; Wan Q; Qi X; Chai Y; Liu X; Chen L; Yan J; Hua Y; Lin F
Mol Cancer Ther; 2020 Oct; 19(10):2001-2011. PubMed ID: 32737157
[No Abstract] [Full Text] [Related]
16. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
17. PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel.
Yang L; Clarke MJ; Carlson BL; Mladek AC; Schroeder MA; Decker P; Wu W; Kitange GJ; Grogan PT; Goble JM; Uhm J; Galanis E; Giannini C; Lane HA; James CD; Sarkaria JN
Clin Cancer Res; 2008 Jun; 14(12):3993-4001. PubMed ID: 18559622
[TBL] [Abstract][Full Text] [Related]
18. Tetraarsenic oxide-induced inhibition of malignant glioma cell invasion in vitro via a decrease in matrix metalloproteinase secretion and protein kinase B phosphorylation.
Gwak HS; Park MJ; Park IC; Woo SH; Jin HO; Rhee CH; Jung HW
J Neurosurg; 2014 Dec; 121(6):1483-91. PubMed ID: 25303017
[TBL] [Abstract][Full Text] [Related]
19. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
[TBL] [Abstract][Full Text] [Related]
20. PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment.
Su JD; Mayo LD; Donner DB; Durden DL
Cancer Res; 2003 Jul; 63(13):3585-92. PubMed ID: 12839945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
